Essential Thrombocythemia Pipeline Outlook Report 2025: Key 6+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Essential Thrombocythemia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Essential Thrombocythemia Pipeline Outlook Report
In August 2025:- Icahn School of Medicine at Mount Sinai conducted a phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary Essential Thrombocythemia (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks).
DelveInsight's Essential Thrombocythemia pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Essential Thrombocythemia treatment.
The leading Essential Thrombocythemia Companies such as PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others.
Promising Essential Thrombocythemia Pipeline Therapies such as Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others.
Discover how the Essential Thrombocythemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Essential Thrombocythemia Clinical Trials and Studies
Essential Thrombocythemia Emerging Drugs Profile
Ropeginterferon alfa-2b: PharmaEssentia
Ropeginterferon alfa-2b is a novel, long-acting, mono-pegylated proline interferon (ATC L03AB15). Its pharmacokinetic properties offer a new level of tolerability. Ropeginterferon alfa-2b is designed to be self-administered subcutaneously with a pen once every two weeks, or monthly during long-term maintenance. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons. PharmaEssentia Corporation is developing a pegylated (PEG) IFN-α product, P1101, for the treatment of ET.
The Phase III multi-site, open-label, randomized, active-controlled study will compare the efficacy, safety, and tolerability and pharmacokinetics of P1101 as second line therapy for ET as compared with anagrelide, a commonly used oral platelet-reduction therapy.
IMG-7289: Imago Biosciences
IMG-7289 (Bomedemstat) is an orally available small molecule, discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, bomedemstat demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other therapeutic agents. The drug is being evaluated in Phase II clinical trial to treat patients with Essential thrombocythaemia, Essential Thrombocythemia, and Polycythaemia Vera. The Drug has been granted orphan and fast track designation from US FDA.
The Essential Thrombocythemia Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Essential Thrombocythemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Essential Thrombocythemia Treatment.
Essential Thrombocythemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Essential Thrombocythemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Essential Thrombocythemia market.
Get a detailed analysis of the latest innovations in the Essential Thrombocythemia pipeline. Explore DelveInsight's expert-driven report today! @ Essential Thrombocythemia Unmet Needs
Essential Thrombocythemia Companies
PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others.
Essential Thrombocythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type
Essential Thrombocythemia Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming Essential Thrombocythemia Therapies and key Developments @ Essential Thrombocythemia Market Drivers and Barriers, and Future Perspectives
Scope of the Essential Thrombocythemia Pipeline Report
Coverage- Global
Essential Thrombocythemia Companies- PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others.
Essential Thrombocythemia Pipeline Therapies- Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others.
Essential Thrombocythemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Essential Thrombocythemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Essential Thrombocythemia drug development? Find out in DelveInsight's exclusive Essential Thrombocythemia Pipeline Report—access it now! @ Essential Thrombocythemia Emerging Drugs and Major Companies
Table of Contents
Introduction
Executive Summary
Essential Thrombocythemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Ropeginterferon alfa-2b: PharmaEssentia
Mid Stage Products (Phase II)
IMG-7289: Imago Biosciences
Early stage products (Phase I/II)
Drug Name: Company Name
Inactive Products
Essential Thrombocythemia Key Companies
Essential Thrombocythemia Key Products
Essential Thrombocythemia- Unmet Needs
Essential Thrombocythemia- Market Drivers and Barriers
Essential Thrombocythemia- Future Perspectives and Conclusion
Essential Thrombocythemia Analyst Views
Essential Thrombocythemia Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/essential-thrombocythemia-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
16 minutes ago
- Globe and Mail
Duke Energy Q2 Earnings Higher Than Estimates, Revenues Rise Y/Y
Duke Energy Corporation 's DUK second-quarter 2025 earnings of $1.25 per share beat the Zacks Consensus Estimate of $1.19 by 5%. The bottom line also improved 10.6% from $1.13 reported in the year-ago quarter, driven by the implementation of new rates and riders. DUK's Total Revenues Total operating revenues came in at $7.51 billion, which rose 4.7% from $7.17 billion in the year-ago period. The top line also beat the Zacks Consensus Estimate of $7.34 billion by 2.3%. The Regulated electric unit's operating revenues were $6.97 billion, up 3.3% year over year, contributing 92.8% to the quarter's total revenues. Revenues from the Regulated natural gas business totaled $462 million, up 33.1% year over year. The Non-regulated Electric and Other segment generated revenues of $78 million, which decreased 1.3% year over year. Highlights of DUK's Earnings Release Duke Energy's total operating expenses amounted to $5.69 billion in the reported quarter, up 4% year over year. The increase was primarily driven by higher expenses for the cost of natural gas, operation, maintenance and other, depreciation and amortization, as well as property and other taxes. The operating income increased 7.2% to $1.83 billion from $1.71 billion recorded in the year-ago quarter. Interest expenses rose to $897 million from $824 million recorded in the second quarter of 2024. For the reported quarter, the average number of customers in its Electric Utilities increased 1.5% year over year. Total electric sales volumes for the reported quarter went down 1.3% year over year to 64,461 gigawatt-hours. DUK's Segmental Highlights Electric Utilities & Infrastructure: This segment's earnings for the second quarter totaled $1,194 million, up from $1,090 million in the second quarter of 2024. Gas Utilities & Infrastructure: Earnings generated from this segment amounted to $6 million, which came in line with the year-ago figure. Other: The segment includes corporate interest expenses not allocated to other business units, resulting from Duke Energy's captive insurance company and other investments. This segment incurred a loss of $228 million compared with a loss of $200 million in the second quarter of 2024. Financial Condition of DUK As of June 30, 2025, Duke Energy had cash & cash equivalents of $344 million, up from $314 million on Dec. 31, 2024. As of June 30, 2025, the long-term debt was $78.91 billion compared with $76.34 billion as of Dec. 31, 2024. During the first six months of 2025, the company generated net cash from operating activities of $5.04 billion compared with $5.43 billion in the same period last year. 2025 Guidance by DUK Duke Energy reaffirmed its 2025 adjusted EPS guidance. The company still expects to generate adjusted EPS in the range of $6.17-$6.42. The Zacks Consensus Estimate for 2025 earnings is pegged at $6.31, which is a bit higher than the midpoint of the company's projected range. DUK continues to project long-term EPS growth of 5-7% through 2029. DUK's Zacks Rank Duke Energy currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Recent Utility Releases American Electric Power Company, Inc. AEP reported second-quarter 2025 operating EPS of $1.43, which beat the Zacks Consensus Estimate of $1.28 by 11.7%. The bottom line inched up 14.4% from $1.25 recorded in the year-ago quarter. AEP's revenues of $5.09 billion rose 11.1% from the year-ago quarter's level of $4.58 billion. The top line also beat the Zacks Consensus Estimate of $4.94 billion by 2.9%. CMS Energy Corporation CMS reported second-quarter 2025 EPS of 71 cents, which outpaced the Zacks Consensus Estimate of 67 cents by 6%. The bottom line also increased 7.6% from 66 cents in the prior-year quarter. Operating revenues totaled $1.84 billion, which surpassed the Zacks Consensus Estimate of $1.69 billion by 9%. The top line also increased 14.4% from $1.61 billion in the prior-year quarter. NextEra Energy, Inc. NEE reported second-quarter 2025 adjusted earnings of $1.05 per share, which topped the Zacks Consensus Estimate of $1.02 by 2.9%. The bottom line was also up nearly 9.4% year over year. In the second quarter, NextEra Energy's operating revenues were $6.7 billion, which missed the Zacks Consensus Estimate of $7.22 billion by 7.28%. However, the top line improved 10.4% year over year. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. NextEra Energy, Inc. (NEE): Free Stock Analysis Report Duke Energy Corporation (DUK): Free Stock Analysis Report American Electric Power Company, Inc. (AEP): Free Stock Analysis Report CMS Energy Corporation (CMS): Free Stock Analysis Report
Globe and Mail
16 minutes ago
- Globe and Mail
Palantir books its first $1 billion in quarterly sales and dodges DOGE axe
NEW YORK (AP) — Shares of Palantir Technologies sailed past previous record highs Tuesday after booking its first $1 billion sales quarter and raising its performance expectations for the year. The stock rose above $170 Tuesday after breaking previous records four times this year in the global artificial intelligence race. The previous high for the stock was set just over a week ago when its stock closed at $158.80. Since going public in 2020 when it posted a $1.17 billion annual loss, the artificial intelligence software company has swung swiftly to a profit and sales are booming. Profit rose 33% to $327 million in the second quarter. Its $1 billion quarterly revenue haul was fueled by a 53% spike in government sales, despite massive spending cuts under President Donald Trump and his Department of Government Efficiency, once led by the world's richest man Elon Musk. 'DOGE has had zero negative impact on Palantir's U.S. government business, which achieved its fastest growth rate since the second quarter of 2021,' wrote William Blair analysts Louie DiPalma and Bryce Sandberg. 'Palantir is clearly benefiting from AI industry momentum across its government and commercial customer bases.' The company also recorded a 93% jump in business sales. Overall U.S. revenue surged 68% to $733 million. Late Monday, Palantir raised its annual revenue expectations to between $4.14 billion and $4.15 billion. It also raised its U.S. commercial revenue guidance to more than $1.3 billion, which would mean that Palantir achieved a growth rate of at least 85%. 'This was a phenomenal quarter,' CEO Alex Karp said in a statement accompanying the earnings release. 'We continue to see the astonishing impact of AI leverage.' Karp believes AI will benefit everyone, saying during a call with industry analysts on Monday that Palantir is, 'bullish on all aspects of American life, including and especially people in the blue collar." He said Palantir wants to 'arm the working class or blue collar workers with AI agency enhancing skills,' and said that the company will reach out to labor leaders to help familiarize workers with the technology. 'People with less than a college education are creating a lot value and sometimes more value than people with a college education using our product,' Karp said. Palantir, headquartered in Denver, specializes in software platforms that pull together and analyze large amounts of data.
CTV News
16 minutes ago
- CTV News
Wall Street traders will get fatter bonuses after riding volatile markets, consultancy says
A group of traders work on the floor of the New York Stock Exchange, Monday, April 14, 2025. (AP Photo/Richard Drew) NEW YORK — Wall Street stock and bond traders can expect their bonuses to jump 10 to 30 per cent this year as they cashed in on turbulent markets, according to a quarterly report by compensation consultancy Johnson Associates. 'All the uncertainty around the tariffs and the continuous upheaval favors volatility and traders,' said the consultancy's founder, Alan Johnson. Other financial employees will not fare as well, with compensation expected to be flat or slightly higher, according to the report. Wealth management and hedge fund executives are estimated to see bonus increases of up to 5 per cent for 2025, while asset managers will likely get bumps of 2 to 7.5 per cent, helped by recovering markets and inflows of client funds. 'Some of the worst effects of the unpredictable U.S. government policies have faded as markets rebounded,' Johnson said. He characterized 2025 as a 'regular' year for compensation, improving from the bad outlook when the new U.S. import tariff policy was announced. Payouts for investment bankers will likely remain muted, even though initial public offerings and M&A deals may rebound in the second half of the year, Johnson said. Because investment banking fees are paid when deals close, which can take months, the compensation for advisory bankers is expected to remain flat or rise a modest five per cent for this year. If the deal activity remains elevated, compensation could improve for 2026, Johnson said. Executives involved with secondary offerings within private equity funds have seen more activity, which could boost their compensation by 10 per cent. Private credit is another area in which payouts could climb 7.5 per cent as asset managers expand their lending activities. --- Reporting by Tatiana Bautzer; editing by Lananh Nguyen and Leslie Adler
